Invention Grant
- Patent Title: Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells
-
Application No.: US16997738Application Date: 2020-08-19
-
Publication No.: US11766454B2Publication Date: 2023-09-26
- Inventor: Irving L. Weissman , Mingye Feng , Jens-Peter Volkmer
- Applicant: The Board of Trustees of the Leland Stanford Junior University
- Applicant Address: US CA Stanford
- Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee: The Board of Trustees of the Leland Stanford Junior University
- Current Assignee Address: US CA Stanford
- Agency: Bozicevic, Field & Francis LLP
- Agent Pamela J. Sherwood
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K35/15 ; A61K31/4745 ; A61K31/713 ; A61K39/39 ; C07K16/28 ; A61K31/519 ; A61K45/06 ; C12N5/0786 ; A61K39/00

Abstract:
Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.
Public/Granted literature
- US20210038643A1 USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS Public/Granted day:2021-02-11
Information query